Business Context and Reporting Period
This Form 8-K is filed by Aadi Bioscience, Inc. (not Whitehawk Therapeutics, Inc.) on December 14, 2023. The filing reports on interim analysis results from the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1/TSC2 inactivating alterations.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on clinical trial updates rather than financial performance data.
Material Changes
The material event reported is the announcement of interim clinical trial results for the PRECISION1 study. No financial material changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Management Commentary
- Event: The Company issued a press release and hosted a conference call/webcast on December 14, 2023, to discuss the interim results.
- Attachments: The press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2) are incorporated by reference for detailed data.
- Risks/Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainties of clinical trial outcomes.
Investor Verification Checklist
- Verify the specific efficacy and safety data from the PRECISION1 trial interim analysis in the attached press release (Exhibit 99.1).
- Review the corporate presentation (Exhibit 99.2) for management's interpretation of the data and future trial timelines.
- Confirm the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial figures.
- Note the discrepancy between the requested company name (Whitehawk Therapeutics) and the filing registrant (Aadi Bioscience).